Middle East and Africa Persistent Corneal Epithelial Defects Treatment Market - Industry Trends and Forecast to 2027

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF MIDDLE EAST AND AFRICA PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRODUCTS LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.10 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 MARKET OVERVIEW

4.1 DRIVERS

4.1.1 INCREASING PREVALENCE OF PERSISTENT CORNEAL EPITHELIAL DEFECTS AND OTHER RELATED COMPLICATIONS

4.1.2 RISING CASES OF EYE SURGERIES AND USAGE OF CONTACT LENSES

4.1.3 GROWING AGEING POPULATION AUGMENTING TOWARDS THE PCED CONDITION

4.1.4 INCREASE IN MECHANICAL TRAUMAS CASES

4.2 RESTRAINT

4.2.1 STRINGENT REGULATORY PROCEDURES

4.2.2 UNMET MEDICAL NEEDS FOR THE TREATMENT OF PCED

4.2.3 HIGH COST OF PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENTS

4.3 OPPORTUNITIES

4.3.1 DEVELOPMENT OF NOVEL THERAPEUTICS

4.3.2 INCREASING AWARENESS ABOUT DIAGNOSIS AND TREATMENT OF THE DISEASE

4.3.3 STRATEGIC INITIATIVES BY MARKET PLAYERS

4.3.4 EMERGING MARKET ECONOMY CREATES SIGNIFICANT OPPORTUNITIES

4.4 CHALLENGES

4.4.1 DEPENDENCY ON THIRD PARTY SUPPLIERS

5 PREMIUM INSIGHTS

6 EPIDEMIOLOGY

7 MIDDLE EAST AND AFRICA PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY CLINICAL CAUSES

7.1 OVERVIEW

7.2 INFLAMMATORY DISEASE

7.3 NEUROTROPHIC KERATITIS (NK)

7.4 EPITHELIAL/LIMBAL STEM CELL DEFICIENCY

7.5 OTHERS

8 MIDDLE EAST AND AFRICA PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE

8.1 OVERVIEW

8.2 DEVICES

8.2.1 BANDAGE CONTACT LENS

8.2.2 AMNIOTIC MEMBRANE GRAFTS

8.2.3 PUNCTAL PLUGS

8.2.3.1 SILICONE PLUG

8.2.3.2 COLLAGEN PLUGS

8.2.4 CORNEAL TRANSPLANTS

8.2.4.1 KERATOPLASTY

8.2.4.2 KERATOPROSTHESIS

8.3 MEDICATION

8.3.1 DRUG TYPE

8.3.1.1 LUBRICANTS

8.3.1.2 PROPHYLACTIC TOPICAL ANTIBIOTICS

8.3.1.2.1 POLYMIXIN B–TRIMETHOPRIM + FLUOROQUINOLONE

8.3.1.2.2 FLUOROQUINOLONE

8.3.1.3 TOPICAL OPHTHALMIC STEROIDS

8.3.1.4 AUTOLOGOUS SERUM TEARS/AUTOLOGOUS SERUM EYE DROPS

8.3.1.5 TETRACYCLINES

8.3.1.6 HUMAN NERVE GROWTH FACTOR (OXERVATE)

8.3.1.7 WOUND HEALING AGENTS

8.3.1.8 OTHERS

8.3.2 ROUTE OF ADMINISTRATION

8.3.2.1 TOPICAL

8.3.2.2 ORAL

9 MIDDLE EAST AND AFRICA PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY END USER

9.1 OVERVIEW

9.2 HOSPITALS

9.3 HOMECARE

9.4 SPECIALTY CLINICS

9.5 OTHERS

10 MIDDLE EAST AND AFRICA PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DISTRIBUTION CHANNEL

10.1 OVERVIEW

10.2 HOSPITAL PHARMACIES

10.3 RETAIL PHARMACIES

10.4 ONLINE PHARMACIES

11 MIDDLE EAST AND AFRICA PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY GEOGRAPHY

11.1 MIDDLE EAST AND AFRICA

11.1.1 UAE

11.1.2 SAUDI ARABIA

11.1.3 SOUTH AFRICA

11.1.4 ISRAEL

11.1.5 KUWAIT

11.1.6 EGYPT

11.1.7 REST OF MIDDLE EAST AND AFRICA

12 MIDDLE EAST AND AFRICA PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, COMPANY LANDSCAPE

12.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA

13 COMPANY PROFILE

13.1 JOHNSON & JOHNSON SERVICES, INC.

13.1.1 COMPANY SNAPSHOT

13.1.2 REVENUE ANALYSIS

13.1.3 COMPANY SHARE ANALYSIS

13.1.4 PRODUCT PORTFOLIO

13.1.5 RECENT DEVELOPMENTS

13.2 ALLERGAN

13.2.1 COMPANY SNAPSHOT

13.2.2 REVENUE ANALYSIS

13.2.3 COMPANY SHARE ANALYSIS

13.2.4 PRODUCT PORTFOLIO

13.2.5 RECENT DEVELOPMENT

13.3 BIO-TISSUE (A SUBSIDIARY OF TISSUETECH, INC.)

13.3.1 COMPANY SNAPSHOT

13.3.2 COMPANY SHARE ANALYSIS

13.3.3 PRODUCT PORTFOLIO

13.3.4 RECENT DEVELOPMENTS

13.4 LABORATOIRES THÉA S.A.S

13.4.1 COMPANY SNAPSHOT

13.4.2 COMPANY SHARE ANALYSIS

13.4.3 PRODUCT PORTFOLIO

13.4.4 RECENT DEVELOPMENT

13.5 NOVARTIS AG

13.5.1 COMPANY SNAPSHOT

13.5.2 REVENUE ANALYSIS

13.5.3 PRODUCT PORTFOLIO

13.5.4 RECENT DEVELOPMENT

13.6 BAUSCH HEALTH

13.6.1 COMPANY SNAPSHOT

13.6.2 REVENUE ANALYSIS

13.6.3 PRODUCT PORTFOLIO

13.6.4 RECENT DEVELOPMENT

13.7 INTEGRA LIFESCIENCES CORPORATION

13.7.1 COMPANY SNAPSHOT

13.7.2 REVENUE ANALYSIS

13.7.3 PRODUCT PORTFOLIO

13.7.4 RECENT DEVELOPMENT

13.8 ALMIRALL, S.A

13.8.1 COMPANY SNAPSHOT

13.8.2 REVENUE ANALYSIS

13.8.3 PRODUCT PORTFOLIO

13.8.4 RECENT DEVELOPMENT

13.9 DOMPÉ FARMACEUTICI S.P.A.

13.9.1 COMPANY SNAPSHOT

13.9.2 PRODUCT PORTFOLIO

13.9.3 RECENT DEVELOPMENTS

13.10 HUNT VALLEY PHARMALAB

13.10.1 COMPANY SNAPSHOT

13.10.2 PRODUCT PORTFOLIO

13.10.3 RECENT DEVELOPMENT

13.11 I-MED PHARMA INC.

13.11.1 COMPANY SNAPSHOT

13.11.2 PRODUCT PORTFOLIO

13.11.3 RECENT DEVELOPMENT

13.12 KALA PHARMACEUTICALS

13.12.1 COMPANY SNAPSHOT

13.12.2 PRODUCT PORTFOLIO

13.12.3 RECENT DEVELOPMENTS

13.13 KATENA PRODUCTS. INC.

13.13.1 COMPANY SNAPSHOT

13.13.2 PRODUCT PORTFOLIO

13.13.3 RECENT DEVELOPMENTS

13.14 NEXT BIOSCIENCES

13.14.1 COMPANY SNAPSHOT

13.14.2 PRODUCT PORTFOLIO

13.14.3 RECENT DEVELOPMENT

13.15 OCULAR SCIENCE, INC.

13.15.1 COMPANY SNAPSHOT

13.15.2 PRODUCT PORTFOLIO

13.15.3 RECENT DEVELOPMENT

13.16 SKYE BIOLOGICS INC.

13.16.1 COMPANY SNAPSHOT

13.16.2 PRODUCT PORTFOLIO

13.16.3 RECENT DEVELOPMENT

14 QUESTIONNAIRE

15 RELATED REPORTS

UU

TABLE 1 MIDDLE EAST AND AFRICA PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY CLINICAL CAUSES, 2018-2027 (USD MILLION)

TABLE 2 MIDDLE EAST AND AFRICA INFLAMMATORY DISEASE IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 3 MIDDLE EAST AND AFRICA NEUROTROPHIC KERATITIS (NK) IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 4 MIDDLE EAST AND AFRICA EPITHELIAL/LIMBAL STEM CELL DEFICIENCY IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 5 MIDDLE EAST AND AFRICA OTHERS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 6 MIDDLE EAST AND AFRICA PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 7 MIDDLE EAST AND AFRICA DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 8 MIDDLE EAST AND AFRICA DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 9 MIDDLE EAST AND AFRICA DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (UNITS)

TABLE 10 MIDDLE EAST AND AFRICA PUNCTAL PLUGS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 11 MIDDLE EAST AND AFRICA CORNEAL TRANSPLANTS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 12 MIDDLE EAST AND AFRICA MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 13 MIDDLE EAST AND AFRICA MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 14 MIDDLE EAST AND AFRICA PROPHYLACTIC TOPICAL ANTIBIOTICS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 15 MIDDLE EAST AND AFRICA MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 16 MIDDLE EAST AND AFRICA PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 17 MIDDLE EAST AND AFRICA HOSPITALS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 18 MIDDLE EAST AND AFRICA HOMECARE IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 19 MIDDLE EAST AND AFRICA SPECIALTY CLINICS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 20 MIDDLE EAST AND AFRICA OTHERS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 21 MIDDLE EAST AND AFRICA PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 22 MIDDLE EAST AND AFRICA HOSPITAL PHARMACIES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 23 MIDDLE EAST AND AFRICA RETAIL PHARMACIES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 24 MIDDLE EAST AND AFRICA ONLINE PHARMACIES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 25 MIDDLE EAST AND AFRICA PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY COUNTRY 2018-2027 (USD MILLION)

TABLE 26 MIDDLE EAST AND AFRICA PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY CLINICAL CAUSES, 2018-2027 (USD MILLION)

TABLE 27 MIDDLE EAST AND AFRICA PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 28 MIDDLE EAST AND AFRICA DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 29 MIDDLE EAST AND AFRICA DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (UNITS)

TABLE 30 MIDDLE EAST AND AFRICA PUNCTAL PLUGS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 31 MIDDLE EAST AND AFRICA CORNEAL TRANSPLANTS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 32 MIDDLE EAST AND AFRICA MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 33 MIDDLE EAST AND AFRICA PROPHYLACTIC TOPICAL ANTIBIOTICS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 34 MIDDLE EAST AND AFRICA MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 35 MIDDLE EAST AND AFRICA PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 36 MIDDLE EAST AND AFRICA PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 37 UAE PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY CLINICAL CAUSES, 2018-2027 (USD MILLION)

TABLE 38 UAE PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 39 UAE DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 40 UAE DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (UNITS)

TABLE 41 UAE PUNCTAL PLUGS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 42 UAE CORNEAL TRANSPLANTS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 43 UAE MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 44 UAE PROPHYLACTIC TOPICAL ANTIBIOTICS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 45 UAE MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 46 UAE PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 47 UAE PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 48 SAUDI ARABIA PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY CLINICAL CAUSES, 2018-2027 (USD MILLION)

TABLE 49 SAUDI ARABIA PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 50 SAUDI ARABIA DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 51 SAUDI ARABIA DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (UNITS)

TABLE 52 SAUDI ARABIA PUNCTAL PLUGS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 53 SAUDI ARABIA CORNEAL TRANSPLANTS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 54 SAUDI ARABIA MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 55 SAUDI ARABIA PROPHYLACTIC TOPICAL ANTIBIOTICS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 56 SAUDI ARABIA MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 57 SAUDI ARABIA PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 58 SAUDI ARABIA PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 59 SOUTH AFRICA PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY CLINICAL CAUSES, 2018-2027 (USD MILLION)

TABLE 60 SOUTH AFRICA PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 61 SOUTH AFRICA DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 62 SOUTH AFRICA DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (UNITS)

TABLE 63 SOUTH AFRICA PUNCTAL PLUGS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 64 SOUTH AFRICA CORNEAL TRANSPLANTS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 65 SOUTH AFRICA MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 66 SOUTH AFRICA PROPHYLACTIC TOPICAL ANTIBIOTICS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 67 SOUTH AFRICA MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 68 SOUTH AFRICA PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 69 SOUTH AFRICA PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 70 ISRAEL PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY CLINICAL CAUSES, 2018-2027 (USD MILLION)

TABLE 71 ISRAEL PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 72 ISRAEL DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 73 ISRAEL DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (UNITS)

TABLE 74 ISRAEL PUNCTAL PLUGS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 75 ISRAEL CORNEAL TRANSPLANTS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 76 ISRAEL MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 77 ISRAEL PROPHYLACTIC TOPICAL ANTIBIOTICS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 78 ISRAEL MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 79 ISRAEL PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 80 ISRAEL PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 81 KUWAIT PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY CLINICAL CAUSES, 2018-2027 (USD MILLION)

TABLE 82 KUWAIT PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 83 KUWAIT DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 84 KUWAIT DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (UNITS)

TABLE 85 KUWAIT PUNCTAL PLUGS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 86 KUWAIT CORNEAL TRANSPLANTS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 87 KUWAIT MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 88 KUWAIT PROPHYLACTIC TOPICAL ANTIBIOTICS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 89 KUWAIT MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 90 KUWAIT PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 91 KUWAIT PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 92 EGYPT PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY CLINICAL CAUSES, 2018-2027 (USD MILLION)

TABLE 93 EGYPT PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 94 EGYPT DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 95 EGYPT DEVICES IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (UNITS)

TABLE 96 EGYPT PUNCTAL PLUGS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 97 EGYPT CORNEAL TRANSPLANTS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 98 EGYPT MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 99 EGYPT PROPHYLACTIC TOPICAL ANTIBIOTICS IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 100 EGYPT MEDICATION IN PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 101 EGYPT PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 102 EGYPT PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 103 REST OF MIDDLE EAST AND AFRICA PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY CLINICAL CAUSES, 2018-2027 (USD MILLION)